Department of Gastrointestinal Surgery, Akershus University Hospital, Lorenskog, Norway.
Department of Surgery, Drammen Hospital, Vestre Viken, Norway.
Br J Surg. 2017 Aug;104(9):1160-1166. doi: 10.1002/bjs.10549. Epub 2017 May 10.
The role of a collagen plug for treating anal fistula is not well established. A randomized prospective multicentre non-inferiority study of surgical treatment of trans-sphincteric cryptogenic fistulas was undertaken, comparing the anal fistula plug with the mucosal advancement flap with regard to fistula recurrence rate and functional outcome.
Patients with an anal fistula were evaluated for eligibility in three centres, and randomized to either mucosal advancement flap surgery or collagen plug, with clinical follow-up at 3 and 12 months. The primary outcome was the fistula recurrence rate. Anal pain (visual analogue scale), anal incontinence (St Mark's score) and quality of life (Short Form 36 questionnaire) were also reported.
Ninety-four patients were included; 48 were allocated to the plug procedure and 46 to advancement flap surgery. The median follow-up was 12 (range 9-24) months. The recurrence rate at 12 months was 66 per cent (27 of 41 patients) in the plug group and 38 per cent (15 of 40) in the flap group (P = 0·006). Anal pain was reduced after operation in both groups. Anal incontinence did not change in the follow-up period. Patients reported an increased quality of life after 3 months. There were no differences between the groups with regard to pain, incontinence or quality of life.
There was a considerably higher recurrence rate after the anal fistula plug procedure than following advancement flap repair. Registration number: NCT01021774 (http://www.clinicaltrials.gov).
胶原塞在治疗肛瘘中的作用尚未得到充分证实。我们开展了一项随机前瞻性多中心非劣效性研究,比较了肛门瘘管栓与黏膜推进瓣治疗经括约肌隐匿性肛瘘的疗效,主要观察指标为肛瘘复发率和功能结局。
在 3 个中心评估患者是否符合入选条件,将符合条件的患者随机分为黏膜推进瓣组或胶原塞组,术后分别于 3 个月和 12 个月进行临床随访。主要结局为肛瘘复发率。同时报告肛门疼痛(视觉模拟评分)、肛门失禁(St Mark 评分)和生活质量(SF-36 问卷)。
共纳入 94 例患者,其中 48 例接受了栓术治疗,46 例接受了推进瓣手术。中位随访时间为 12(9-24)个月。12 个月时,栓术组的复发率为 66%(41 例中的 27 例),而推进瓣组的复发率为 38%(40 例中的 15 例)(P=0·006)。两组术后肛门疼痛均有所缓解。随访期间肛门失禁无变化。术后 3 个月时患者生活质量均有所提高。两组在疼痛、失禁和生活质量方面无差异。
与黏膜推进瓣修复术相比,肛门瘘管栓术后的复发率明显更高。注册号:NCT01021774(http://www.clinicaltrials.gov)。